Mike Doustdar seeks to reassure investors that Novo Nordisk's Wegovy pill will drive profitable growth despite pricing pressures.
Novo Nordisk CEO Mike Doustdar reported that the company's Wegovy pill is positioned to drive profitable growth despite ongoing pricing pressures. While the company's shares fell following a quarterly report that showed better-than-expected adjusted sales and operating profit, Mike Doustdar emphasized that rising volumes and the early performance of the Wegovy pill demonstrate a successful strategy. The pill has reached over 5 million prescriptions since its launch, with 80% of patients using it for the first time. Despite the positive outlook on the Wegovy pill, investors remain concerned about intensifying competition from Eli Lilly's Zepbound and Mounjaro. The administration also pressured the company to implement price cuts to improve patient access. Novo Nordisk is also developing next-generation therapies like CagriSema to maintain its market position. Analysts suggest that while the company has a strong position in the diabetes and obesity markets, the near-term outlook remains challenging due to high operating expenses and the rapid ascent of its primary rival, Eli Lilly.